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Transurethral resection of bladder tumor remains the most common procedure for the diagnosis,
management, and treatment of bladder cancer. Deep resection of the detrusor muscle for the correct
staging of bladder cancer can increase the risk of hemorrhage that can be difﬁcult to control with
standard transurethral surgical maneuvers. Evicel Fibrin Sealant was applied transurethrally to manage
difﬁcult hemorrhage following transurethral resection of bladder tumor in two surgically complex
bladder cancer patients. Our early experience suggests Evicel can be an effective tool in managing
difﬁcult to control hemorrhage associated with TURBT. Further clinical investigation is to be encouraged.
 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Transurethral resection of bladder tumor (TURBT) remains the
standard for both the initial diagnosis and treatment of bladder
cancer. The aims of TURBT include: (1) establishing the histology of
the tumor; (2) identifying the depth of tumor invasion; (3) deter-
mining important prognostic factors; (4) achieving complete
removal of all visible tumors.1
While TURBT is a common procedure, on any individual case a
surgeon may not always achieve these desired goals. In particular,
deep resection of the detrusor muscle (DM) is essential for correct
staging.1 The absence of DM in resection specimens from pub-
lished series ranges from 30e50% and is associated with a higher
risk of residual disease in pT1 tumors, with up to 40% of tumors
upstaged to pT2.2 Trials investigating re-TURBT have reported
detection rates of residual tumor cells of 30e75% across all tumor
stages.3
This clinical need to perform deeper TURBT to secure DM in the
specimen exposes the patient to a greater risk of perioperative
complications. A recent analysis of TURBT complications demon-
strated that patients who experienced a complication were older,
presented with a lower hemoglobin level, more tumors, larger tu-
mors and more co-morbidities.4 Several studies have conﬁrmed
that postoperative bleeding is the most common complication
associated with TURBT.4terests or product support.
nc. This is an open access article uCurrent maneuvers to deal with persistent TURBT hemorrhage
are limited to cauterization techniques. Endoscopic cautery tools
include monopolar and bipolar loops, roller ball, “Button,” and
Bugbee electrodes. In the event these maneuvers fail, persistent
bleeding from vascular channels following TURBT that includes DM
can be a source of signiﬁcant morbidity.
Case presentation
Patient A is a male patient currently 72 years old with a history
of aortic valve replacement onWarfarin and requires coverage with
Lovenox for surgical procedures. He underwent Holmium laser
enucleation of the prostate on 1/26/12 and suffered an embolic
event despite anticoagulant coverage.
He began experiencing intermittent gross hematuria in May
2013 that he attributed to his Warfarin use. Eventually, contrast
enhanced CT scan revealed a large right sided bladder mass and
Urovysion was positive for malignant cells. He agreed to proceed
with TURBT with the assurance that anticoagulant coverage would
be continued.
Warfarin was held, Lovenox was started, and he returned to the
operating room on 10/24/13. Cystoscopy revealed the right trigone
replaced by a large, actively bleeding, sessile mass. Monopolar
TURBT was performed resecting deep through the detrusor to
expose perivesical fat. Actively bleeding tumor that could not be
completely resected was exposed posterior to the bladder. Hem-
orrhage remained brisk despite all standard surgical maneuvers.
The decision was made to apply Evicel Fibrin Sealant transur-
ethrally in an effort to secure adequate hemostasis. Consent was
secured from appropriate family members. Irrigationwas slowed to
allow visualization while minimizing disruption of this hemostaticnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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catheter was passed through the resectoscope and into the deepest
extent of the resection site (Fig. 1). Both components of Evicel
were slowly injected through this catheter, mixing at the tip, and
completely ﬁlled the resection site. The Evicel was allowed to set
for 10 minutes. Cystoscopy revealed an opaque, ﬁbrin plug ﬁlling
the resection cavity and no further active bleeding. A 3-way cath-
eter was placed to gravity drainage without continuous irrigation.
Lovenox was restarted postoperatively and Warfarin was
restarted on postoperative day 2. Intermittent gross hematuria
persistedwithout clots and continuous bladder irrigationwas never
needed. Urine remained clear and the catheter was removed on
postoperative day 10. Pathology documented high-grade transi-
tional cell carcinoma with muscularis propria invasion.
He elected to proceed with radiation and chemotherapy, which
he completed without any episodes of gross hematuria. He agreed
to surveillance cystoscopy on 3/7/14, which revealed a deep,
necrotic ulcer on the right trigone without active bleeding. Repeat
TURBT was performed on 7/17/2014 for recurrent gross hematuria
and pathology revealed necrosis, and no malignancy. He is
currently being treated for metastatic disease without gross
hematuria.
Patient B is a female patient currently 88 years old who elected
not to report gross hematuria over a 12-month period. Cystoscopy
on 3/18/15 revealed a large right lateral wall bladder tumor. TURBT
was performed 4/9/15 with resection exposing perivesical fat. A
very thin detrusor wall, an extremely lateral extent of gross tumor,
and obturator nerve stimulation, all complicated efforts at resec-
tion. Hemorrhage from extravesical venous channels remained
troublesome despite standard surgical maneuvers.
Evicel use was discussed and consent was secured from
appropriate family members. Evicel Fibrin Sealant was applied
transurethrally into the resection site using the technique outlined
above to secure adequate hemostasis. Cystoscopy after application
revealed awell-formed ﬁbrin plug ﬁlling the resection cavity and no
further active bleeding. Patient B was monitored postoperatively
without continuousbladder irrigation.Her catheterwas removedon
postoperative day 10. Pathology was reported as low-grade uro-
thelial carcinoma negative for muscularis propria invasion.
She refused additional treatment other than surveillance
cystoscopy, which revealed a visible, stable ﬁbrin plug within the
resection site and no gross tumor on 5/20/15. On 8/19/15 Urovysion
was negative, and cystoscopy demonstrated intact bladder mucosaFigure 1. Evicel Fibrin Sealant (Human) (Ethicon, Inc.) and proprietary endoscopic
application catheter.with typical scar formation and no visible tumor. She has not
experienced any further episodes of gross hematuria since her
initial resection.
Discussion
Fibrin sealants have been utilized in the United States to achieve
surgical hemostasis for two decades.5 Although these products
contain human-derived thrombin and ﬁbrinogen there have been
no reported cases of hepatitis or AIDS transmission.6 Typically, the
thrombin and ﬁbrinogen components are delivered to the bleeding
tissue to achieve hemostasis. Some products also contain anti-
ﬁbrinolytic agents, but these have been associated with adverse
outcomes.5
Evicel Fibrin Sealant (Ethicon, Inc.) is packaged as a kit con-
taining one frozen vial of human ﬁbrinogen and one frozen vial of
human thrombin. There are no antiﬁbrinolytic components in
Evicel. This product is indicated as an adjunct to hemostasis when
control of bleeding by standard surgical techniques is ineffective or
impractical.5
Evicel has been demonstrated to be safe, effective, and superior
to Surgicel absorbable hemostat in achieving hemostasis for mild
to moderate bleeding in soft tissue during urologic surgery.5 Fibrin
clots formed with Evicel have also demonstrated a stronger and
more resistant ﬁbrin clot than that formed by Tisseel (Baxter), an
aprotininecontaining ﬁbrin sealant.7 While Evicel is now
commonly utilized in both laparoscopic and open urologic surgery,
we report the ﬁrst transurethral use of Evicel to control signiﬁcant
hemorrhage following deep TURBT.
Conclusion
Evicel Fibrin Sealant is FDA approved for topical use and its
transurethral application should be considered an appropriate off-
label medical use. It is not expected to be efﬁcacious for brisk
arterial bleeding due to rapid wash off. Evicel should not be
injected directly into the circulatory system due to the risk of a
thromboembolic event. Evicel emulates the last phase of physio-
logic blood coagulation. Thrombin activates the conversion of
ﬁbrinogen into ﬁbrin, which occurs by the splitting of ﬁbrinogen
into ﬁbrin monomers and ﬁbrinopeptides. The ﬁbrin monomers
aggregate and form a ﬁbrin clot. Factor XIIIa, which is activated by
thrombin, crosslinks the ﬁbrin monomers into an even stronger
clot. Fibrin sealants like Evicel are metabolized by ﬁbrinolysis and
phagocytosis in the same way as endogenous ﬁbrin. As wound
healing progresses ﬁbrinolytic activity is induced by plasmin and
the decomposition of ﬁbrin-to-ﬁbrin crosslinked monomers
proceeds.
Evicel Fibrin Sealant has been demonstrated to be a safe and
effective hemostatic sealant in a wide variety of laparoscopic and
open urologic operations. Our patients document a beneﬁcial,
transurethral performance of this product. Our early experience
suggests Evicel can be an effective tool in managing difﬁcult to
control hemorrhage associated with TURBT. Further clinical inves-
tigation is to be encouraged.
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